Putzke Jörg, Spina Mariarosa G, Büchler Jochen, Kovar Karl-Artur, Wolf Gerald, Smalla Karl-Heinz
Institute of Medical Neurobiology, OvG-University, Germany.
Addict Biol. 2007 Mar;12(1):69-80. doi: 10.1111/j.1369-1600.2006.00047.x.
Repeated administration of beta-phenylalkylamines is known to produce neuronal changes in the central and peripheral nervous systems of mammals. It is suggested that various components of the cytoskeleton undergo profound alterations after amphetamine use and misuse, contributing to behavioral changes and neurotoxicity. Here we studied the expression of microtubule-associated protein 2 (MAP2) and beta-actin after repeated intraperitoneal applications with equimolar doses of p-chloroamphetamine (PCA), methamphetamine (METH) and 3,4-methylenedioxymethamphetamine (MDMA) in the brain of male Wistar rats. Effective (molecular) pharmacological doses (ED) were derived and used for the calculation of (molecular) pharmacological indices (PI). Besides clear but different dose-response curves on the toxicity of the drugs, in situ hybridization and Western blot analysis revealed that repeated administration of these compounds resulted in different substance- and dose-dependent changes in MAP2 gene expression, e.g. in the frontoparietal somatosensoric cortex. In contrast, the expression of beta-actin was not influenced by any of the compounds at the dose levels tested. Lethal doses were determined with 2.1 (PCA), >5.1 (METH) and 8.4 mg/kg/day (MDMA). Linear and non-linear repeat-dose lethality was observed for MDMA and PCA, respectively, whereas METH was non-lethal in the dose range used. Values for ED(MAP2) were 0.3, 0.52 and >16.8 mg/kg/day, and therefore those for PI(MAP2) were 20, 4, and 0.5 for METH, PCA and MDMA, respectively. Although the results on mortality did not reflect changes in MAP2 gene expression, they suggest a remarkable difference for those amphetamines without substituents or with a halogen atom at the paraposition of the benzene ring, such as METH or PCA, when compared with MDMA-like substances.
已知反复给予β-苯烷基胺会在哺乳动物的中枢和外周神经系统中产生神经元变化。有人提出,在使用和滥用苯丙胺后,细胞骨架的各种成分会发生深刻改变,从而导致行为变化和神经毒性。在此,我们研究了在雄性Wistar大鼠脑内反复腹腔注射等摩尔剂量的对氯苯丙胺(PCA)、甲基苯丙胺(METH)和3,4-亚甲基二氧基甲基苯丙胺(MDMA)后,微管相关蛋白2(MAP2)和β-肌动蛋白的表达。得出有效(分子)药理剂量(ED)并用于计算(分子)药理指数(PI)。除了这些药物毒性方面清晰但不同的剂量反应曲线外,原位杂交和蛋白质印迹分析表明,反复给予这些化合物会导致MAP2基因表达出现不同的物质和剂量依赖性变化,例如在额顶躯体感觉皮层。相比之下,在所测试的剂量水平下,β-肌动蛋白的表达不受任何一种化合物的影响。致死剂量分别为2.1(PCA)、>5.1(METH)和8.4毫克/千克/天(MDMA)。MDMA和PCA分别观察到线性和非线性重复剂量致死性,而METH在所使用的剂量范围内无致死性。ED(MAP2)值分别为0.3、0.52和>16.8毫克/千克/天,因此METH、PCA和MDMA的PI(MAP2)值分别为20、4和0.5。尽管死亡率结果并未反映MAP2基因表达的变化,但它们表明,与MDMA类物质相比,那些无取代基或在苯环对位带有卤原子的苯丙胺,如METH或PCA,存在显著差异。